Art. -Nr.: HY-107767

Antibiotic DC 81

(Synonyms: DC 81)

Antibiotic DC 81 (DC 81), an antitumor antibiotic produced by Streptomyces species, is a PBD (pyrrolo[2,1-c][1,4]benzodiazepine). Antibiotic DC 81 is potent inhibitor of nucleic acid synthesis. Antibiotic DC 81 can recognize and bind to specific sequences of DNA and form a labile covalent adduct.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 81307-24-6
Formel: C₁₃H₁₄N₂O₃
Molecular Weight:246.26

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (273 KB)

Antibiotic DC 81 Chemical Structure

CAS. Nr.: 81307-24-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	GI₅₀	0.14 μM Compound: DC-81	Growth inhibition of human A2780 cells by SRB method Growth inhibition of human A2780 cells by SRB method	[PMID: 18207392]
A2780	GI₅₀	0.14 μM Compound: 3, DC-81	Growth inhibition of human A2780 cells after 48 hrs by SRB assay Growth inhibition of human A2780 cells after 48 hrs by SRB assay	[PMID: 20031423]
A2780	GI₅₀	0.14 μM Compound: 1, DC-81	Cytotoxicity against human A2780 cells after 48 hrs by SRB assay Cytotoxicity against human A2780 cells after 48 hrs by SRB assay	[PMID: 20444601]
A2780	GI₅₀	0.14 μM Compound: DC-81	Cytotoxicity against human A2780 cells after 48 hrs by SRB assay Cytotoxicity against human A2780 cells after 48 hrs by SRB assay	[PMID: 20554354]
A2780	GI₅₀	0.14 μM Compound: 4, DC-81	Anticancer activity against human A2780 cells after 48 hrs by SRB assay Anticancer activity against human A2780 cells after 48 hrs by SRB assay	[PMID: 20557981]
A2780	GI₅₀	0.14 μM Compound: 3, DC-81	Cytotoxicity against human A2780 cells after 48 hrs by SRB assay Cytotoxicity against human A2780 cells after 48 hrs by SRB assay	[PMID: 20673627]
A2780	GI₅₀	0.14 μM Compound: 1, DC-81	Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay Cytotoxicity against human A2780 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
A2780	GI₅₀	0.14 μM Compound: 2, DC-81	Cytotoxicity against human A2780 cells by sulforhodamine B method Cytotoxicity against human A2780 cells by sulforhodamine B method	[PMID: 21459581]
A2780	GI₅₀	0.14 μM Compound: 1, DC-81	Anticancer activity against human A2780 cells by SRB method Anticancer activity against human A2780 cells by SRB method	[PMID: 21676506]
A2780	GI₅₀	0.14 μM Compound: 3, DC-81	Anticancer activity against human A2780 cells by SRB method Anticancer activity against human A2780 cells by SRB method	[PMID: 22104151]
A2780	GI₅₀	0.14 μM Compound: 1, DC-81	Growth inhibition of human A2780 cells Growth inhibition of human A2780 cells	10.1039/C1MD00072A
A-431	IC₅₀	1.65 μM Compound: I, DC-81	Anticancer activity against human A431 cells after 48 hrs by MTT assay Anticancer activity against human A431 cells after 48 hrs by MTT assay	[PMID: 22209733]
A549	GI₅₀	0.16 μM Compound: DC-81	Growth inhibition of human A549 cells by SRB method Growth inhibition of human A549 cells by SRB method	[PMID: 18207392]
A549	GI₅₀	0.16 μM Compound: 3, DC-81	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	[PMID: 20031423]
A549	GI₅₀	0.16 μM Compound: 1, DC-81	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 20444601]
A549	GI₅₀	0.16 μM Compound: DC-81	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 20554354]
A549	GI₅₀	0.16 μM Compound: 3, DC-81	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 20673627]
A549	GI₅₀	0.16 μM Compound: 1, DC-81	Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay Cytotoxicity against human A549 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
A549	GI₅₀	0.16 μM Compound: 2, DC-81	Cytotoxicity against human A549 cells by sulforhodamine B method Cytotoxicity against human A549 cells by sulforhodamine B method	[PMID: 21459581]
A549	GI₅₀	0.16 μM Compound: 1, DC-81	Anticancer activity against human A549 cells by SRB method Anticancer activity against human A549 cells by SRB method	[PMID: 21676506]
A549	GI₅₀	0.16 μM Compound: 3, DC-81	Anticancer activity against human A549 cells by SRB method Anticancer activity against human A549 cells by SRB method	[PMID: 22104151]
A549	IC₅₀	1.11 μM Compound: I, DC-81	Anticancer activity against human A549 cells after 48 hrs by MTT assay Anticancer activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22209733]
A549	GI₅₀	0.16 μM Compound: 1, DC-81	Growth inhibition of human A549 cells Growth inhibition of human A549 cells	10.1039/C1MD00072A
CH1	IC₅₀	0.1 μM Compound: 5	Tested for cytotoxicity against CH1 human ovarian cells Tested for cytotoxicity against CH1 human ovarian cells	[PMID: 10354403]
CH1	IC₅₀	0.1 μM Compound: 3	In vitro cytotoxicity against ovarian carcinoma cell line CH1. In vitro cytotoxicity against ovarian carcinoma cell line CH1.	[PMID: 10514273]
CHO-AA8	IC₅₀	2 μM Compound: 31 (DC-81)	In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure	[PMID: 12747786]
COLO 205	GI₅₀	0.11 μM Compound: DC-81	Growth inhibition of human Colo205 cells by SRB method Growth inhibition of human Colo205 cells by SRB method	[PMID: 18207392]
COLO 205	GI₅₀	0.11 μM Compound: 3, DC-81	Growth inhibition of human COLO205 cells after 48 hrs by SRB assay Growth inhibition of human COLO205 cells after 48 hrs by SRB assay	[PMID: 20031423]
COLO 205	GI₅₀	0.11 μM Compound: 1, DC-81	Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay	[PMID: 20444601]
COLO 205	GI₅₀	0.11 μM Compound: DC-81	Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay	[PMID: 20554354]
COLO 205	GI₅₀	0.11 μM Compound: 3, DC-81	Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay Cytotoxicity against human COLO205 cells after 48 hrs by SRB assay	[PMID: 20673627]
COLO 205	GI₅₀	0.11 μM Compound: 1, DC-81	Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay Cytotoxicity against human COLO205 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
COLO 205	GI₅₀	0.11 μM Compound: 2, DC-81	Cytotoxicity against human COLO205 cells by sulforhodamine B method Cytotoxicity against human COLO205 cells by sulforhodamine B method	[PMID: 21459581]
COLO 205	GI₅₀	0.11 μM Compound: 1, DC-81	Anticancer activity against human COLO205 cells by SRB method Anticancer activity against human COLO205 cells by SRB method	[PMID: 21676506]
COLO 205	GI₅₀	0.11 μM Compound: 3, DC-81	Anticancer activity against human COLO205 cells by SRB method Anticancer activity against human COLO205 cells by SRB method	[PMID: 22104151]
COLO 205	IC₅₀	0.86 μM Compound: I, DC-81	Anticancer activity against human COLO205 cells after 48 hrs by MTT assay Anticancer activity against human COLO205 cells after 48 hrs by MTT assay	[PMID: 22209733]
COLO 205	GI₅₀	0.11 μM Compound: 1, DC-81	Growth inhibition of human COLO205 cells Growth inhibition of human COLO205 cells	10.1039/C1MD00072A
EMT6	IC₅₀	1100 nM Compound: 31 (DC-81)	In vitro cellular toxicity against murine mammary carcinoma EMT6 cell line after 4 hr of compound exposure In vitro cellular toxicity against murine mammary carcinoma EMT6 cell line after 4 hr of compound exposure	[PMID: 12747786]
HOP-62	GI₅₀	0.15 μM Compound: 3, DC-81	Growth inhibition of human HOP62 cells after 48 hrs by SRB assay Growth inhibition of human HOP62 cells after 48 hrs by SRB assay	[PMID: 20031423]
HOP-62	GI₅₀	0.15 μM Compound: 1, DC-81	Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay	[PMID: 20444601]
HOP-62	GI₅₀	0.15 μM Compound: DC-81	Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay	[PMID: 20554354]
HOP-62	GI₅₀	0.15 μM Compound: 3, DC-81	Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay Cytotoxicity against human HOP62 cells after 48 hrs by SRB assay	[PMID: 20673627]
HOP-62	GI₅₀	0.15 μM Compound: 1, DC-81	Cytotoxicity against human HOP62 cells after 24 hrs by WST-1 assay Cytotoxicity against human HOP62 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
HOP-62	GI₅₀	0.15 μM Compound: 2, DC-81	Cytotoxicity against human HOP62 cells by sulforhodamine B method Cytotoxicity against human HOP62 cells by sulforhodamine B method	[PMID: 21459581]
HOP-62	GI₅₀	0.15 μM Compound: 1, DC-81	Anticancer activity against human HOP62 cells by SRB method Anticancer activity against human HOP62 cells by SRB method	[PMID: 21676506]
HOP-62	GI₅₀	0.15 μM Compound: 1, DC-81	Growth inhibition of human HOP62 cells Growth inhibition of human HOP62 cells	10.1039/C1MD00072A
HT-29	IC₅₀	30.19 μM Compound: 16b, DC-81	Cytotoxicity against human HT29 cells by MTT assay Cytotoxicity against human HT29 cells by MTT assay	[PMID: 18538566]
HT-29	IC₅₀	30.19 μmol Compound: 16b, DC-81	Cytotoxicity against human HT29 cells by MTT assay Cytotoxicity against human HT29 cells by MTT assay	[PMID: 18538566]
Jurkat	IC₅₀	2.2 μM Compound: 9, DC-81	Antiproliferative activity against human Jurkat cells Antiproliferative activity against human Jurkat cells	[PMID: 17081759]
K562	IC₅₀	1 μM Compound: 9, DC-81	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 17081759]
KB	GI₅₀	0.17 μM Compound: DC-81	Growth inhibition of human KB cells by SRB method Growth inhibition of human KB cells by SRB method	[PMID: 18207392]
KB	GI₅₀	0.17 μM Compound: 3, DC-81	Growth inhibition of human KB cells after 48 hrs by SRB assay Growth inhibition of human KB cells after 48 hrs by SRB assay	[PMID: 20031423]
KB	GI₅₀	0.17 μM Compound: 1, DC-81	Cytotoxicity against human KB cells after 48 hrs by SRB assay Cytotoxicity against human KB cells after 48 hrs by SRB assay	[PMID: 20444601]
KB	GI₅₀	0.17 μM Compound: DC-81	Cytotoxicity against human KB cells after 48 hrs by SRB assay Cytotoxicity against human KB cells after 48 hrs by SRB assay	[PMID: 20554354]
KB	GI₅₀	0.17 μM Compound: 4, DC-81	Anticancer activity against human KB cells after 48 hrs by SRB assay Anticancer activity against human KB cells after 48 hrs by SRB assay	[PMID: 20557981]
KB	GI₅₀	0.17 μM Compound: 3, DC-81	Cytotoxicity against human KB cells after 48 hrs by SRB assay Cytotoxicity against human KB cells after 48 hrs by SRB assay	[PMID: 20673627]
KB	GI₅₀	0.17 μM Compound: 1, DC-81	Cytotoxicity against human KB cells after 24 hrs by WST-1 assay Cytotoxicity against human KB cells after 24 hrs by WST-1 assay	[PMID: 20732817]
KB	GI₅₀	0.17 μM Compound: 2, DC-81	Cytotoxicity against human KB cells by sulforhodamine B method Cytotoxicity against human KB cells by sulforhodamine B method	[PMID: 21459581]
KB	GI₅₀	0.17 μM Compound: 1, DC-81	Anticancer activity against human KB cells by SRB method Anticancer activity against human KB cells by SRB method	[PMID: 21676506]
KB	GI₅₀	0.17 μM Compound: 3, DC-81	Anticancer activity against human KB cells by SRB method Anticancer activity against human KB cells by SRB method	[PMID: 22104151]
KB	GI₅₀	0.17 μM Compound: 1, DC-81	Growth inhibition of human KB cells Growth inhibition of human KB cells	10.1039/C1MD00072A
L1210	IC₅₀	0.38 μM Compound: 5	Tested for cytotoxicity against L1210 Leukemia cell Tested for cytotoxicity against L1210 Leukemia cell	[PMID: 10354403]
L1210	IC₅₀	0.38 μM Compound: DC-81	In vitro cytotoxicity was evaluated in L1210 cell line In vitro cytotoxicity was evaluated in L1210 cell line	[PMID: 14505647]
L1210	IC₅₀	0.38 μM Compound: DC-81	In vitro cytotoxicity against leukemia L1210 cell line In vitro cytotoxicity against leukemia L1210 cell line	[PMID: 14698184]
L1210	IC₅₀	0.38 μM Compound: DC-81	Compound was tested for inhibitory activity against L1210 cell line Compound was tested for inhibitory activity against L1210 cell line	[PMID: 15225736]
L1210	IC₅₀	0.38 μM Compound: DC-81	In vitro cytotoxicity against mouse leukemia L1210 cell lines In vitro cytotoxicity against mouse leukemia L1210 cell lines	[PMID: 15341949]
L1210	IC₅₀	0.38 μM Compound: DC-81, 2	Cytotoxicity against mouse L1210 cells Cytotoxicity against mouse L1210 cells	[PMID: 18378445]
L1210	IC₅₀	0.38 μM Compound: DC-81	Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210 Tested in vitro for inhibition after 48 hr exposure against murine leukemia cell line L1210	[PMID: 7996544]
MCF7	GI₅₀	0.17 μM Compound: DC-81	Growth inhibition of human MCF7 cells by SRB method Growth inhibition of human MCF7 cells by SRB method	[PMID: 18207392]
MCF7	GI₅₀	0.17 μM Compound: 3, DC-81	Growth inhibition of human MCF7 cells after 48 hrs by SRB assay Growth inhibition of human MCF7 cells after 48 hrs by SRB assay	[PMID: 20031423]
MCF7	GI₅₀	0.17 μM Compound: 1, DC-81	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 20444601]
MCF7	GI₅₀	0.17 μM Compound: DC-81	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 20554354]
MCF7	GI₅₀	0.17 μM Compound: 3, DC-81	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	[PMID: 20673627]
MCF7	GI₅₀	0.17 μM Compound: 1, DC-81	Cytotoxicity against human MCF7 cells after 24 hrs by WST-1 assay Cytotoxicity against human MCF7 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
MCF7	GI₅₀	0.17 μM Compound: 2, DC-81	Cytotoxicity against human MCF7 cells by sulforhodamine B method Cytotoxicity against human MCF7 cells by sulforhodamine B method	[PMID: 21459581]
MCF7	GI₅₀	0.17 μM Compound: 1, DC-81	Anticancer activity against human MCF7 cells by SRB method Anticancer activity against human MCF7 cells by SRB method	[PMID: 21676506]
MCF7	GI₅₀	0.17 μM Compound: 3, DC-81	Anticancer activity against human MCF7 cells by SRB method Anticancer activity against human MCF7 cells by SRB method	[PMID: 22104151]
MCF7	GI₅₀	0.17 μM Compound: 1, DC-81	Growth inhibition of human MCF7 cells Growth inhibition of human MCF7 cells	10.1039/C1MD00072A
MCF7	IC₅₀	5 μM Compound: 1, DC-81	Cytotoxicity against human MCF7 cells assessed as reduction cell viability after 24 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as reduction cell viability after 24 hrs by MTT assay	10.1039/C2MD20219K
PC-3	GI₅₀	0.2 μM Compound: DC-81	Growth inhibition of human PC3 cells by SRB method Growth inhibition of human PC3 cells by SRB method	[PMID: 18207392]
PC-3	GI₅₀	0.2 μM Compound: 3, DC-81	Growth inhibition of human PC3 cells after 48 hrs by SRB assay Growth inhibition of human PC3 cells after 48 hrs by SRB assay	[PMID: 20031423]
PC-3	GI₅₀	0.2 μM Compound: 1, DC-81	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 20444601]
PC-3	GI₅₀	0.2 μM Compound: DC-81	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 20554354]
PC-3	GI₅₀	0.2 μM Compound: 3, DC-81	Cytotoxicity against human PC3 cells after 48 hrs by SRB assay Cytotoxicity against human PC3 cells after 48 hrs by SRB assay	[PMID: 20673627]
PC-3	GI₅₀	0.2 μM Compound: 1, DC-81	Cytotoxicity against human PC3 cells after 24 hrs by WST-1 assay Cytotoxicity against human PC3 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
PC-3	GI₅₀	0.2 μM Compound: 2, DC-81	Cytotoxicity against human PC3 cells by sulforhodamine B method Cytotoxicity against human PC3 cells by sulforhodamine B method	[PMID: 21459581]
PC-3	GI₅₀	0.2 μM Compound: 1, DC-81	Anticancer activity against human PC3 cells by SRB method Anticancer activity against human PC3 cells by SRB method	[PMID: 21676506]
PC-3	IC₅₀	1.19 μM Compound: I, DC-81	Anticancer activity against human PC3 cells after 48 hrs by MTT assay Anticancer activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 22209733]
PC-3	GI₅₀	0.2 μM Compound: 1, DC-81	Growth inhibition of human PC3 cells Growth inhibition of human PC3 cells	10.1039/C1MD00072A
PC-6	IC₅₀	0.33 μM Compound: DC-81	In vitro cytotoxicity was evaluated in PC6 cell line In vitro cytotoxicity was evaluated in PC6 cell line	[PMID: 14505647]
PC-6	IC₅₀	0.33 μM Compound: DC-81	In vitro cytotoxicity against leukemia PC6 cell line In vitro cytotoxicity against leukemia PC6 cell line	[PMID: 14698184]
PC-6	IC₅₀	0.33 μM Compound: DC-81	Compound was tested for inhibitory activity against PC6 cell line Compound was tested for inhibitory activity against PC6 cell line	[PMID: 15225736]
PC-6	IC₅₀	0.33 μM Compound: DC-81	In vitro cytotoxicity against human lung cancer PC-6 cells lines In vitro cytotoxicity against human lung cancer PC-6 cells lines	[PMID: 15341949]
PC-6	IC₅₀	0.33 μM Compound: DC-81, 2	Cytotoxicity against human PC6 cells Cytotoxicity against human PC6 cells	[PMID: 18378445]
SiHa	GI₅₀	0.17 μM Compound: DC-81	Growth inhibition of human SiHa cells by SRB method Growth inhibition of human SiHa cells by SRB method	[PMID: 18207392]
SiHa	GI₅₀	0.17 μM Compound: 3, DC-81	Growth inhibition of human SiHa cells after 48 hrs by SRB assay Growth inhibition of human SiHa cells after 48 hrs by SRB assay	[PMID: 20031423]
SiHa	GI₅₀	0.17 μM Compound: 1, DC-81	Cytotoxicity against human SiHa cells after 48 hrs by SRB assay Cytotoxicity against human SiHa cells after 48 hrs by SRB assay	[PMID: 20444601]
SiHa	GI₅₀	0.17 μM Compound: DC-81	Cytotoxicity against human SiHa cells after 48 hrs by SRB assay Cytotoxicity against human SiHa cells after 48 hrs by SRB assay	[PMID: 20554354]
SiHa	GI₅₀	0.17 μM Compound: 4, DC-81	Anticancer activity against human SiHa cells after 48 hrs by SRB assay Anticancer activity against human SiHa cells after 48 hrs by SRB assay	[PMID: 20557981]
SiHa	GI₅₀	0.17 μM Compound: 3, DC-81	Cytotoxicity against human SiHa cells after 48 hrs by SRB assay Cytotoxicity against human SiHa cells after 48 hrs by SRB assay	[PMID: 20673627]
SiHa	GI₅₀	0.17 μM Compound: 1, DC-81	Cytotoxicity against human SiHa cells after 24 hrs by WST-1 assay Cytotoxicity against human SiHa cells after 24 hrs by WST-1 assay	[PMID: 20732817]
SiHa	GI₅₀	0.17 μM Compound: 2, DC-81	Cytotoxicity against human SiHa cells by sulforhodamine B method Cytotoxicity against human SiHa cells by sulforhodamine B method	[PMID: 21459581]
SiHa	GI₅₀	0.17 μM Compound: 1, DC-81	Anticancer activity against human SiHa cells by SRB method Anticancer activity against human SiHa cells by SRB method	[PMID: 21676506]
SiHa	GI₅₀	0.16 μM Compound: 3, DC-81	Anticancer activity against human SiHa cells by SRB method Anticancer activity against human SiHa cells by SRB method	[PMID: 22104151]
SiHa	GI₅₀	0.17 μM Compound: 1, DC-81	Growth inhibition of human SiHa cells Growth inhibition of human SiHa cells	10.1039/C1MD00072A
SK-OV-3	IC₅₀	1900 nM Compound: 31 (DC-81)	In vitro cellular toxicity against human ovarian carcinoma SKOV3 cell line after 4 hr of compound exposure In vitro cellular toxicity against human ovarian carcinoma SKOV3 cell line after 4 hr of compound exposure	[PMID: 12747786]
UV4	IC₅₀	1500 nM Compound: 31 (DC-81)	In vitro cellular toxicity against chinese hamster UV4 cell line after 4 hr of compound exposure In vitro cellular toxicity against chinese hamster UV4 cell line after 4 hr of compound exposure	[PMID: 12747786]
ZR-75-1	GI₅₀	2.37 μM Compound: DC-81	Growth inhibition of human Zr-75-1 cells by SRB method Growth inhibition of human Zr-75-1 cells by SRB method	[PMID: 18207392]
ZR-75-1	GI₅₀	2.37 μM Compound: 3, DC-81	Growth inhibition of human ZR-75-1 cells after 48 hrs by SRB assay Growth inhibition of human ZR-75-1 cells after 48 hrs by SRB assay	[PMID: 20031423]
ZR-75-1	GI₅₀	2.37 μM Compound: 1, DC-81	Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay	[PMID: 20444601]
ZR-75-1	GI₅₀	2.37 μM Compound: DC-81	Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay	[PMID: 20554354]
ZR-75-1	GI₅₀	2.37 μM Compound: 4, DC-81	Anticancer activity against human ZR-75-1 cells after 48 hrs by SRB assay Anticancer activity against human ZR-75-1 cells after 48 hrs by SRB assay	[PMID: 20557981]
ZR-75-1	GI₅₀	2.37 μM Compound: 3, DC-81	Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay Cytotoxicity against human ZR-75-1 cells after 48 hrs by SRB assay	[PMID: 20673627]
ZR-75-1	GI₅₀	2.37 μM Compound: 1, DC-81	Cytotoxicity against human ZR-75-1 cells after 24 hrs by WST-1 assay Cytotoxicity against human ZR-75-1 cells after 24 hrs by WST-1 assay	[PMID: 20732817]
ZR-75-1	GI₅₀	2.37 μM Compound: 2, DC-81	Cytotoxicity against human ZR-75-1 cells by sulforhodamine B method Cytotoxicity against human ZR-75-1 cells by sulforhodamine B method	[PMID: 21459581]
ZR-75-1	GI₅₀	2.37 μM Compound: 1, DC-81	Anticancer activity against human ZR-75-1 cells by SRB method Anticancer activity against human ZR-75-1 cells by SRB method	[PMID: 21676506]
ZR-75-1	GI₅₀	2.37 μM Compound: 3, DC-81	Anticancer activity against human ZR-75-1 cells by SRB method Anticancer activity against human ZR-75-1 cells by SRB method	[PMID: 22104151]
ZR-75-1	GI₅₀	2.34 μM Compound: 1, DC-81	Growth inhibition of human ZR-75-1 cells Growth inhibition of human ZR-75-1 cells	10.1039/C1MD00072A

In Vitro

Antibiotic DC 81 shows cytotoxicity against human melanoma cell lines B16, A375, A2058, and RPMI7951, with IC₅₀ values of 4.4 μM, 18.5 μM, 31.0 μM, and 41.5 μM, respectively^[1]^[2].
Antibiotic DC 81 exhibits its biological activity by covalently binding to the N2 of guanine in the minor groove of DNA, via the electrophilic carbinolamine functionality at N10-C11^[1].
Antibiotic DC 81 (4 μM, 24 h) induces mitochondria dependent apoptosis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[2]

Cell Line:

B16 melanoma cells
Concentration:

4 μM
Incubation Time:

24 h
Result:

Induced mitochondria dependent apoptosis.

In Vivo

Antibiotic DC 81 (0-10 mg/kg, i.p., at day 4, 7, 10, 13 after tumor cell injection) decreases the tumor burden in tumor-bearing mice, but the Antibiotic DC 81 at 10 mg/kg impairs cardiac muscle enzyme and liver function significantly^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female C57BL/6 mice (8-12 weeks old, B16 cells were injected into the tail veins of mice)^[2]
Dosage:

0.1, 1, 10 mg/kg
Administration:

i.p., at day 4, 7, 10, 13 after tumor cell injection
Result:

Substantially decreased the tumor burden by 20% at 1 mg/kg. DC-81 at 10 mg/kg induced an 8-10-fold increase of GPT and a 6-8-fold increase in CPK, which indicated severe impaired liver function and muscle damage. Did not impair significant renal function as demonstrated by serum creatinine.

Chemical Information

CAS. Nr. 81307-24-6
Molecular Weight 246.26
Formel C₁₃H₁₄N₂O₃
SMILES

O=C1C2=CC(OC)=C(O)C=C2N=C[C@@]3([H])N1CCC3
Synonyms

DC 81
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (273 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hu WP, et al. Biological evaluation of an antibiotic DC-81-indole conjugate agent in human melanoma cell lines. Kaohsiung J Med Sci. 2003 Jan;19(1):6-12. [Content Brief]

[2]. Lee CH, et al. Pyrrolo[2,1-c][1,4]benzodiazepine and indole conjugate (IN6CPBD) has better efficacy and superior safety than the mother compound DC-81 in suppressing the growth of established melanoma in vivo. Chem Biol Interact. 2009 Aug 14;180(3):360-7. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Antibiotic DC 81

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

Antibiotic DC 81 Related Classifications

HY-107767 Related Classifications